Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
Andreas SchneeweissTjoung-Won Park-SimonJoan AlbanellUlrik LassenJavier CortésVeronique DierasMarcus MayChristoph SchindlerFrederik MarméJuan Miguel CejalvoMaria Martinez-GarciaIria GonzalezJose Lopez-MartinAnja WeltChristelle LevyFlorence JolyFrancesca MichielinWolfgang JacobCéline AdessiAnnie MoisanGeorgina Meneses-LorenteTomas RacekIan JamesMaurizio CeppiMax HasmannMartin WeisserAndrés CervantesPublished in: Investigational new drugs (2018)
on ClinicalTrials.gov with the identifier NCT01918254 first registered on 3rd July 2013.